Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-29 07:35:25 - browse：22193

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Naloxone nonprofit donates 200,000 doses after FDA approval

WSS

FDA panel signals lack of confidence in Amgen cancer drug data

Maui's cultural, historic landmarks damaged in the devastating wildfires

Liquid biopsy for lung cancer is launched by Delfi

3 questions for the future of Biden's cancer moonshot

NIH trials fail to test meaningful long Covid therapies, experts say

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Naloxone nonprofit donates 200,000 doses after FDA approval

Walensky prepares to leave CDC — and Congress — behind

How to use technology to prevent future drug shortages

As demand for Covid shots wanes, Moderna seeks its next success

Bill would stop addiction treatment from triggering child abuse inquiry

Medicare details structure of new drug price negotiation program

Chemotherapy drug shortage eases slightly but still widespread

Peter Hotez and the public health issue of online harassment

Why Charlie Gard's case is so disturbing to Americans

entertainment

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Histogen: Failed biotech offers rare public look inside

Police still searching for prisoner who escaped from NYC hospital

VC firm General Catalyst wants to buy a health system

Phenylephrine and the overlooked value of the placebo effect

Bill would stop addiction treatment from triggering child abuse inquiry

explore

explore

entertainment

explore